General Department, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, Wuhan, China.
Department of Infection Management, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, Wuhan, China.
BMC Gastroenterol. 2021 Aug 4;21(1):314. doi: 10.1186/s12876-021-01887-2.
Ulcerative colitis is a common non-specific chronic disease. Supplementing probiotics has become an important method for the treatment of ulcerative colitis. This study aimed to explore the effect of supplementing bifid triple viable capsules on background mesalazine plus somatostatin on plasma inflammatory factors and T cell frequency in ulcerative colitis patients.
A total of 130 ulcerative colitis patients admitted to our hospital from August 2018 to March 2020 were included and divided into the experimental group (65 patients with mesalazine plus somatostatin and bifid triple viable capsules for treatment) and the control group (65 patients treated with mesalazine plus somatostatin) using the random number table method. Bifid triple viable bacteria capsules were given orally, 420 mg each time, with 3 times a day for 2 months.
Before treatment, the plasma levels of IL-6, IL-8, hs-CRP, TNF-α, D-lactic acid, and endotoxin (ET), CD4+, CD8+, CD4/CD8 ratio, diamine oxidase (DA0), emotional ability, social ability, intestinal and systemic symptoms were not significantly different between the two groups (all P > 0.05). After treatment, the plasma levels of IL-6, IL-8, hs-CRP, and TNF-α decreased in both groups, and were lower in the experimental group than those in the control group (all P < 0.05). The levels of CD4+ and CD4/CD8 ratio increased, and were higher in the experimental group than those in the control group (P < 0.05); the CD8+ levels were reduced, and were lower in the experimental group than those in the control group (P < 0.05). The plasma D-lactic acid, ET, and DA0 levels were decreased, and were lower in the experimental group than those in the control group; emotional ability, social ability, intestinal and systemic symptoms were improved, and were higher in the experimental group than those in the control group (all P < 0.05). During the course of treatment, 2 cases of abdominal discomfort and 1 case of rash occurred in the experimental group, with an adverse event rate of 4.62% (3/65); 3 cases of abdominal discomfort and 2 cases of rash occurred in the control group, with an adverse event rate of 7.69% (5/65).
The supplementary treatment of bifid triple viable capsules can effectively enhance the curative effect in ulcerative colitis patients, reduce plasma inflammatory factors, and regulate T cell frequency, which is worthy of clinical application.
溃疡性结肠炎是一种常见的非特异性慢性疾病。补充益生菌已成为治疗溃疡性结肠炎的重要方法。本研究旨在探讨补充双歧三联活菌胶囊对柳氮磺胺吡啶加生长抑素治疗溃疡性结肠炎患者血浆炎症因子和 T 细胞频率的影响。
选取 2018 年 8 月至 2020 年 3 月我院收治的溃疡性结肠炎患者 130 例，采用随机数字表法分为实验组（65 例给予柳氮磺胺吡啶加生长抑素加双歧三联活菌胶囊治疗）和对照组（65 例给予柳氮磺胺吡啶加生长抑素治疗）。双歧三联活菌胶囊口服，每次 420mg，每日 3 次，治疗 2 个月。
治疗前，两组患者血浆白细胞介素-6（IL-6）、白细胞介素-8（IL-8）、超敏 C 反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）、D-乳酸、内毒素（ET）、CD4+、CD8+、CD4/CD8 比值、二胺氧化酶（DAO）、情绪能力、社会能力、肠道和全身症状比较，差异均无统计学意义（均 P＞0.05）。治疗后，两组患者血浆 IL-6、IL-8、hs-CRP 和 TNF-α 水平降低，实验组低于对照组（均 P＜0.05）；CD4+和 CD4/CD8 比值升高，实验组高于对照组（P＜0.05）；CD8+水平降低，实验组低于对照组（P＜0.05）。两组患者血浆 D-乳酸、ET、DAO 水平降低，实验组低于对照组；情绪能力、社会能力、肠道和全身症状改善，实验组优于对照组（均 P＜0.05）。治疗过程中，实验组出现腹痛 2 例、皮疹 1 例，不良反应发生率为 4.62%（3/65）；对照组出现腹痛 3 例、皮疹 2 例，不良反应发生率为 7.69%（5/65）。
补充双歧三联活菌胶囊治疗溃疡性结肠炎可有效提高疗效，降低血浆炎症因子水平，调节 T 细胞频率，值得临床应用。
